Participated · Equity · Sep 2025

Inbox Health offers a cloud platform that uses artificial intelligence to generate clear, personalized medical bills and to automate multi-channel payment collection for healthcare providers. Patients can pay via credit card, digital wallet, ACH, phone or check, and can interact with human or AI support agents in 60 languages through calls, chat and email. The system feeds real-time payment posting, analytics and feedback dashboards back to practice staff, aiming to cut administrative workload and reduce unpaid balances. Recent partnerships include an enterprise rollout with CHE Behavioral Health Services and a deepened integration with Greenway Health’s Intergy EHR via the Greenway Marketplace. The company plans to devote new capital to further AI research focused on emotional intelligence and faster issue resolution. Since inception, Inbox Health has raised $55 million in equity financing across multiple rounds to fuel product expansion and market penetration.

Participated · Series B · Apr 2022

Covr offers a digital life insurance platform that lets users compare rates from carriers and purchase policies within minutes. The company provides its digital insurance solutions to financial institutions under their own brands and supports distribution through financial advisors and insurance producers. Covr serves over 25,000 financial advisors and more than 40 million customers across over 30 financial institutions. Led by CEO Michael Kalen, the company aggregates life insurance products from carriers and streamlines the purchasing experience. Covr plans to use new funding to continue building its digital insurance technology and to support a number of distribution partnerships. The platform focuses on improving the customer experience for banks and other financial institutions that distribute life insurance. Covr operates a digital platform that enables banks, credit unions and fintech apps to offer white-labeled life insurance integrated into their websites and distribution channels. Several insurers underwrite policies on the platform, including Americo, Banner Life, Bestow and Haven Life. Covr says it serves over 25,000 financial advisers and more than 20 million customers across 30+ financial institutions. The company launched LoanMatch Protector, a life insurance product for consumer and business loans, in January. Covr plans to use new funding to expand its provider partnerships and accelerate domestic and international growth, leveraging Sony’s distribution network. The company was founded in 2016 and is based in Hartford, Connecticut, and currently plans to grow headcount from about 90 to 110 employees by year-end. Its advisory board includes former and current executives from Credit Suisse, Citibank, Ellevest, Visa, Lending Club and Rockefeller Capital Management. Covr Financial Technologies offers a digital, multi-carrier life insurance platform that enables financial advisors and consumers to research and purchase affordable life insurance within minutes. The company provides both digital advisor and consumer platforms used by brokerage firms and consumer banks. Covr serves a customer base representing 20,000 financial advisors and over eight million consumers, and its roster includes firms such as Morgan Stanley, US Bank and SunTrust. Founded in 2012 and led by CEO Mike Kalen, the company is headquartered in Boise, Idaho and also has offices in Hartford and Austin. Covr has raised more than $20m in total funding to date and intends to use new funds to continue to innovate and support its client base. Covr Financial Technologies is a digital personal insurance platform that integrates personal insurance products from nearly twenty major insurers into financial institutions and financial advisers' channels. The platform offers education and training on insurance products, insurance-product marketing, and insurance-licensed telephone support. Led by CEO Bill Benjamin, Covr enables financial firms to deliver an integrated line of personal insurance products digitally to their customers. The company is based in Boise, Idaho, and also has a presence in New York and Minneapolis. Covr raised $5M in funding to support strategic growth and talent expansion, reflecting an active capital position as of the article.

Participated · Equity · Jul 2020

Covr is a Hartford-based, digital-first insurance technology company that simplifies the insurance journey for financial advisors and financial institutions. It offers life insurance, long-term care, disability income and supplemental insurance products through a choice-based, digitally enabled platform. The company says it supports over 25,000 financial advisors and 20 million customers of financial institutions. Founded in 2016, Covr has a team of 69 people. Its current financial position includes $28.3 million in total funding to date. Management plans to use enhanced AI, big data and predictive tools in its next series of innovations to improve customer journeys and product fit. Covr Financial Technologies operates a digital personal insurance platform that allows personal insurance shoppers to purchase coverage online. The company provides relevant education and training on insurance products alongside its purchasing flow. Its platform is distributed via financial institutions and their financial advisors. Founded in 2013 and formerly known as 1ClickCoverage, Covr focuses on simplifying the insurance buying process. The company announced a $5 million financing from Nyca Partners, Commerce Ventures, Connectivity Capital Partners and Contour Venture Partners. CEO Bill Benjamin cited the firm's access to executives from insurance, technology, marketing and financial industries as a competitive edge.

Participated · Series B · May 2020

Rallybio is focused on therapies for rare maternal–fetal diseases, principally RLYB212, a human monoclonal anti‑HPA‑1a antibody designed to prevent alloimmunization that causes FNAIT. The company is running a natural history study to support a future registrational study and plans a phase 2 dose‑confirmation trial for RLYB212 in the second half of this year. Rallybio describes RLYB212 as the only known clinical‑stage therapy designed to prevent FNAIT in pregnant individuals who haven’t alloimmunized. Its other lead program, RLYB116, is a C5 inhibitor the company believes could treat diseases involving complement dysregulation. Rallybio noted there are currently no approved therapies specifically preventing or prenatally treating FNAIT. The company recently reduced headcount and refocused on two phase‑2‑ready programs to extend cash runway; it entered 2024 with $109.9 million in cash, cash equivalents and marketable securities. Rallybio pursues an agnostic, disease-agnostic approach to develop therapies for rare diseases, focusing on small molecules and proteins including antibodies. Its lead asset, RLYB-211, is a hyperimmune globulin acquired from a small Norwegian startup to treat fetal and neonatal alloimmune thrombocytopenia (FNAIT) via antibody-mediated immune suppression. FNAIT currently has no approved treatment and can cause miscarriage, neonatal death, or neurological disability from fetal brain bleeding. The company raised $145 million in a Series B to advance RLYB-211 into a Phase 1/2 study in the second half of this year and to support its broader pipeline. Its pipeline also includes RLYB-212 for a rare blood disease and three preclinical protein therapeutics targeting immune-inflammatory diseases; Rallybio expects to move RLYB-212 and one preclinical program into the clinic next year. Rallybio sources assets worldwide through partnerships and acquisitions and has a discovery deal with Exscientia signed last July. The founders have said the company will not work in oncology or infectious disease and will continue to focus on modalities it believes can move the needle in rare diseases. Rallybio is a biotechnology company established to identify and accelerate the development of transformative therapies for patients with severe and rare disorders. The company focuses on developing drug candidates including antibodies, small molecules and engineered proteins against mechanisms with strong biological rationale. Rallybio plans to identify and advance therapeutic candidates this year. It was co-founded in January 2018 by Martin Mackay, PhD, Stephen Uden, MD, and Jeffrey Fryer, CPA, all industry veterans with extensive experience in drug discovery, development, and finance. The company is based in Farmington, Connecticut at the University of Connecticut's Technology Incubation Program. Rallybio secured $37.0 million in Series A financing to support its early discovery and development efforts.